Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ).
Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure. This committee is responsible for overseeing the selection of directors and senior management, ensuring a diverse and independent board composition, and aligning the board’s skills with the company’s corporate strategies. The formation of this committee is part of the company’s efforts to comply with relevant laws and improve its corporate governance.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. The company operates within the biotechnology sector, focusing on the development and production of vaccines and related technologies. It is listed on The Stock Exchange of Hong Kong Limited, indicating its engagement in international markets.
Average Trading Volume: 134,028
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.71B
Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.